US2018250322A1PendingUtilityA1

Antibodies which bind type i cannabinoid receptor/angiotensis ii receptor heteromers

Assignee: ICAHN SCHOOL MED MOUNT SINAIPriority: Jan 25, 2010Filed: Dec 12, 2017Published: Sep 6, 2018

Est. expiryJan 25, 2030(~3.5 yrs left)· nominal 20-yr term from priority

Inventors:Lakshmi A. Devi Raphael Rozenfeld

C07K 16/286C07K 2317/76C07K 2317/32C07K 16/44A61K 31/7076A61K 31/454C07K 16/2869C07K 2317/31

PatentIndex Score

Cited by

References

Claims

Abstract

Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.

Claims

exact text as granted — not AI-modified

1 - 45 . (canceled) 
     
     
         46 . An isolated monoclonal antibody which specifically binds to a type I cannabinoid receptor (CB 1 R)/adenosine 2a receptor (A2aR) heteromer. 
     
     
         47 . A pharmaceutical composition comprising the monoclonal antibody of  claim 46  and a pharmaceutically acceptable carrier or diluent.

Join the waitlist — get patent alerts

Track US2018250322A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.